Multidrug-Resistant Bacterial Infections in U.S.

Original Article �Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017

1. Original Article Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017 John A. Jernigan, M.D., Kelly M. Hatfield, M.S.P.H., Hannah Wolford, M.S.P.H., Richard E. Nelson, Ph.D., Babatunde Olubajo, Ph.D., Sujan C. Reddy, M.D., Natalie McCarthy, M.P.H., Prabasaj Paul, Ph.D., L. Clifford McDonald, M.D., Alex Kallen, M.D., Anthony Fiore, M.D., Michael Craig, M.P.P., and James Baggs, Ph.D. N Engl J Med Volume 382(14):1309-1319 April 2, 2020

2. Study Overview This article provides U.S. national estimates for six common nosocomial pathogens. The incidence of infection decreased for four (MRSA, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter species, and multidrug-resistant P. aeruginosa ), was constant for one (carbapenem-resistant Enterobacteriaceae), and increased for one (ESBL-producing Enterobacteriaceae).

3. Estimated Number of Cases of Multidrug-Resistant Bacterial Infection in the United States, According to Year and Location Onset, 2012–2017. Jernigan JA et al. N Engl J Med2020;382:1309-1319

4. Characteristics of All Included Hospitals and Patients, According to Year, as Compared with the Distribution of U.S. Hospitals as Provided by the AHA. Jernigan JA et al. N Engl J Med2020;382:1309-1319

5. National Estimates of Resistant Infections, According to Pathogen, 2012–2017. Jernigan JA et al. N Engl J Med2020;382:1309-1319

6. Continuous Trend Analysis of Adjusted National Incidence Trends, According to Pathogen and Location Onset, 2012–2017. Jernigan JA et al. N Engl J Med2020;382:1309-1319

7. Conclusions Health care–associated antimicrobial resistance places a substantial burden on patients in the United States. Further work is needed to identify improved interventions for both the inpatient and outpatient settings.